Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders

[1]  M. Heuser,et al.  SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications , 2012, Leukemia.

[2]  A. Tefferi,et al.  SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients , 2012, Leukemia.

[3]  Michael Heuser,et al.  Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. , 2012, Blood.

[4]  A. Jankowska,et al.  Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. , 2012, Blood.

[5]  A. Jankowska,et al.  SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts , 2012, Leukemia.

[6]  J. Maciejewski,et al.  Polycomb segment myeloid malignancies. , 2012, Blood.

[7]  Shiho Suzuki,et al.  Overexpression of MCM2 in myelodysplastic syndromes: association with bone marrow cell apoptosis and peripheral cytopenia. , 2012, Experimental and molecular pathology.

[8]  Li Ding,et al.  RECURRENT MUTATIONS IN THE U2AF1 SPLICING FACTOR IN MYELODYSPLASTIC SYNDROMES , 2011, Nature Genetics.

[9]  G. Garcia-Manero,et al.  SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. , 2012, Blood.

[10]  E. Giné,et al.  Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia , 2011, Nature Genetics.

[11]  L. Pasqualucci,et al.  Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. , 2011, Blood.

[12]  Peter J Campbell,et al.  Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms , 2011, Blood.

[13]  Y. Mizui,et al.  Biological validation that SF3b is a target of the antitumor macrolide pladienolide , 2011, The FEBS journal.

[14]  A. Sivachenko,et al.  SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. , 2011, The New England journal of medicine.

[15]  A. Jankowska,et al.  Acquired Molecular Defects in Spliceosome Machinery: Novel Pathogenetic Pathways in Myeloid Leukemogenesis , 2011 .

[16]  A. Jankowska,et al.  Association of SF3B1 with Ring Sideroblasts in patients, In Vivo, and In Vitro models of Spliceosomal Dysfunction , 2011 .

[17]  A. Jankowska,et al.  Mechanisms of Defective Hydroxylation of 5-Methylcytosine in MDS Include Pathways Other Than TET2 and IDH1/2 , 2011 .

[18]  S. Miyano,et al.  Mutational Spectrum Analysis of Interesting Correlation and Interrelationship Between RNA Splicing Pathway and Commonly Targeted Genes in Myelodysplastic Syndrome , 2011 .

[19]  S. Ogawa,et al.  SRSF2 is Mutated in 47.2% (77/163) of Chronic Myelomonocytic Leukemia (CMML) and Prognostically Favorable in Cases with Concomitant RUNX1 mutations , 2011 .

[20]  A. Jankowska,et al.  Impact of Molecular Mutations on Treatment Response to Hypomethylating Agents in MDS , 2011 .

[21]  M. Stratton,et al.  Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. , 2011, The New England journal of medicine.

[22]  S. Sugano,et al.  Frequent pathway mutations of splicing machinery in myelodysplasia , 2011, Nature.

[23]  A. Jankowska,et al.  Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. , 2011, Blood.

[24]  B. Gazzard,et al.  Plasma HHV8 DNA predicts relapse in individuals with HIV-associated multicentric Castleman disease. , 2011, Blood.

[25]  H. Heimpel,et al.  Sideroblastic anemia: molecular analysis of the ALAS2 gene in a series of 29 probands and functional studies of 10 missense mutations , 2011, Human mutation.

[26]  M. Cazzola,et al.  Ring sideroblasts and sideroblastic anemias , 2011, Haematologica.

[27]  S. Hammond,et al.  Genetic therapies for RNA mis-splicing diseases. , 2011, Trends in genetics : TIG.

[28]  E. Brambilla,et al.  Acetylation and phosphorylation of SRSF2 control cell fate decision in response to cisplatin , 2011, The EMBO journal.

[29]  J. Adams,et al.  Phosphorylation mechanism and structure of serine‐arginine protein kinases , 2011, The FEBS journal.

[30]  Joshua F. McMichael,et al.  DNMT3A mutations in acute myeloid leukemia. , 2010, The New England journal of medicine.

[31]  J. Manley,et al.  Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. , 2010, Genes & development.

[32]  A. Jankowska,et al.  Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies , 2010, Leukemia.

[33]  T. Cooper,et al.  The pathobiology of splicing , 2010, The Journal of pathology.

[34]  S. Morris,et al.  Synthetic mRNA splicing modulator compounds with in vivo antitumor activity. , 2009, Journal of medicinal chemistry.

[35]  D. Richardson,et al.  Mitochondrial Iron Metabolism and Sideroblastic Anemia , 2009, Acta Haematologica.

[36]  J. Manley,et al.  Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches , 2009, Nature Reviews Molecular Cell Biology.

[37]  M. Moore,et al.  Meayamycin inhibits pre–messenger RNA splicing and exhibits picomolar activity against multidrug-resistant cells , 2009, Molecular Cancer Therapeutics.

[38]  Toralf Kirsten,et al.  Evolution of Spliceosomal snRNA Genes in Metazoan Animals , 2008, Journal of Molecular Evolution.

[39]  T. Halfdanarson,et al.  Hematological manifestations of copper deficiency: a retrospective review , 2008, European journal of haematology.

[40]  Brian C. Rymond.  Targeting the spliceosome , 2007, Nature Chemical Biology.

[41]  Xiang-Dong Fu,et al.  Splicing Regulator SC35 Is Essential for Genomic Stability and Cell Proliferation during Mammalian Organogenesis , 2007, Molecular and Cellular Biology.

[42]  D. Steensma,et al.  Candidate gene mutation analysis in idiopathic acquired sideroblastic anemia (refractory anemia with ringed sideroblasts). , 2007, Leukemia research.

[43]  L. Trinkle-Mulcahy,et al.  Emerging roles of nuclear protein phosphatases , 2007, Nature Reviews Molecular Cell Biology.

[44]  R. Sachidanandam,et al.  Comprehensive splice-site analysis using comparative genomics , 2006, Nucleic acids research.

[45]  S. Valadkhan.  snRNAs as the catalysts of pre-mRNA splicing. , 2005, Current opinion in chemical biology.

[46]  F. Clark,et al.  Understanding alternative splicing: towards a cellular code , 2005, Nature Reviews Molecular Cell Biology.

[47]  R. Guigó,et al.  Are splicing mutations the most frequent cause of hereditary disease? , 2005, FEBS letters.

[48]  T. Komori,et al.  Mammalian polycomb-mediated repression of Hox genes requires the essential spliceosomal protein Sf3b1. , 2005, Genes & development.

[49]  D. Richardson,et al.  Iron trafficking in the mitochondrion: novel pathways revealed by disease. , 2005, Blood.

[50]  Claudia Schneider,et al.  A novel U2 and U11/U12 snRNP protein that associates with the pre‐mRNA branch site , 2001, The EMBO journal.

[51]  J. Melkko,et al.  Acetaldehyde Adducts in Blood and Bone Marrow of Patients With Ethanol-Induced Erythrocyte Abnormalities , 2001, Molecular medicine.

[52]  R J Wyatt,et al.  Elevated concentration of N-CAM VASE isoforms in schizophrenia. , 2000, Journal of psychiatric research.

[53]  G. Schellenberg,et al.  Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[54]  Molly M. Huntsman,et al.  Altered ratios of alternatively spliced long and short γ2 subunit mRNAs of the γ-amino butyrate type A receptor in prefrontal cortex of schizophrenics , 1998 .

[55]  Lin Jin,et al.  Aberrant RNA Processing in a Neurodegenerative Disease: the Cause for Absent EAAT2, a Glutamate Transporter, in Amyotrophic Lateral Sclerosis , 1998, Neuron.

[56]  A. J. Lopez,et al.  Alternative splicing of pre-mRNA: developmental consequences and mechanisms of regulation. , 1998, Annual review of genetics.

[57]  J. Corden,et al.  A CTD function linking transcription to splicing. , 1997, Trends in biochemical sciences.

[58]  C. Roberts,et al.  Altered expression of the WT1 wilms tumor suppressor gene in human breast cancer. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[59]  J. Bruner,et al.  Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[60]  C. Thompson,et al.  bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death , 1993, Cell.

[61]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.